Novo Nordisk A/s

Cytoki Pharma Aps

Henning Thøgersen

Per Sauerberg

Jesper F Lau

Patrick William Garibay

Thomas Kruse

Thomas Hoeg-Jensen

Michael Paolo Bastner Sandrini

Sebastian Beck Jørgensen

Lauge Schäffer

Peter Madsen

Ingrid Pettersson

Janos Tibor Kodra

Christian Klarner Sams

Carsten Behrens

Michael Bruno Plewe

Jane Spetzler

Birgit Wieczorek

Steffen Reedtz-Runge

Shenghua Shi

Anthony Lai Ling

Tina Møller Tagmose

Brian Finan

Larry Kenneth Truesdale

János Tibor Kodra

Ulla Grove Sidelmann

Ivan Snajdr

Patrick J Knerr

Ladislav Droz

Rasmus Jørgensen

Kristian Sass-Ørum

Vladislav Kotek

Milan Stengl

Fa Liu

Søren Østergaard

Jakob Ewald Rasmussen

Wouter Frederik Johan Hogendorf

Behrend Frederik Lundt

Bírgítte Andersen

Anker Steen Jøgensen

Inge Thøger Christensen

Nicholas Raymond Cox

Martin Werner Borchsenius MÜNZEL

Richard Dimarchi

Mikael Kofoed Hansen

Vojtech BALSÁNEK

Zuzana DROBNÁKOVÁ

Hana VÁNOVÁ

Miroslav HAVRÁNEK

Steffen Runge

The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.

Therapeutic derivatives of interleukin-22

The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.

FGF21 derivatives with albumin binder A-B-C-D-E- and their use

Amylin derivatives, pharmaceutical compositions containing such derivatives, as well as methods of treating diabetes and hyperglycaemia are disclosed.

Amylin derivatives

The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.

Glucagon-Like Peptide-1 derivatives and their pharmaceutical use

A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.

Glucagon antagonists/inverse agonists

Growing community of inventors

Farum, Denmark

Henning Thøgersen